Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBK_L2201 in Postmenopausal Women With Osteoporosis
NCT06154187Phase 3Not yet recruiting
- Sponsor
- Pharmbio Korea Inc.
- Start
- Feb 2024
- Primary completion
- May 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of abaloparatide in osteoporosis, sponsored by Pharmbio Korea Inc.. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
abaloparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT06154187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06154187.